CG Oncology released positive results from the Phase 3 BOND-003 trial in high-risk Non-Muscle Invasive Bladder Cancer patients. 74.5% achieved a complete response after treatment with cretostimogene. The median duration of response exceeds 27 months.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing